No Data
No Data
ADR Japan Stock Ranking: Overall selling trend dominated by institutions including Yucho Bank; Chicago at 37,770 yen is 40 yen higher than Osaka.
ADR (American Depositary Receipt) of Japanese stocks, converted to 1 dollar/153.92 yen against the Tokyo Stock Exchange, with Yucho Bank <7182>, Recruit HD <6098>, Advantest <6857>, Sony <6758>, Renesas <6723>, Nintendo <7974>, Shin-Etsu Chemical <4063> all falling, general selling pressure. The settlement price of Chicago Nikkei 225 futures is 37,770 yen, up 40 yen compared to the Osaka daytime market. The U.S. stock market is mixed. The Dow was up 81.20 dollars at 39,935.
Fujitsu has turned a profit in the first quarter with a profit and loss of 21.3 billion yen.
Fujitsu (6702) announced that its Q1 financial results for the fiscal year ending March 2025 showed sales revenue of 830.03 billion yen, a 3.8% increase YoY, and operating profit of 21.387 billion yen (compared to a loss of 1.88 billion yen in the same period last year), exceeding the consensus estimate of about 1.77 billion yen. The company's main IT services business, driven by the DX demand, performed well domestically. For the fiscal year ending March 2025, sales revenue is expected to be 3,760 billion yen, a slight increase of 0.1% over the previous year, and operating profit is expected to increase by 16.3%, reaching 330 billion yen.
Chugai Pharmaceutical's H1 Profits and Dividends Up
Nikkei Average Contribution Ranking (Closing)~ The Nikkei Average fell significantly for the seventh consecutive day, with SoftBank G and TEL pushing down about 334 yen with two stocks.
At the closing bell on the 25th, the number of rising stocks in the Nikkei index was 35, the number of falling stocks was 189, and the number of unchanged stocks was 1. The US stock market on the 24th continued to fall, with the Dow Jones Industrial Average closing at 39,853.87, down 504.22 dollars (-1.25%), the Nasdaq down 654.94 points (-3.64%) at 17,342.41, and the S&P 500 down 128.61 points (-2.31%) at 5,427.13. Disappointed by the lackluster earnings of some high-tech companies.
Chugai Pharmaceutical: Supplementary information for the consolidated financial statements (IFRS) for the second quarter (interim) of the period ending in December 2024.
Chugai Pharmaceutical: Interim financial results (IFRS) for the second quarter of December 2024. (Consolidated)
No Data